We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Genocea Biosciences Inc | NASDAQ:GNCA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.051 | 0.01 | 0.05 | 0 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
Siber George |
2. Issuer Name
and
Ticker or Trading Symbol
GENOCEA BIOSCIENCES, INC. [ GNCA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
2000 BROADWAY, PENTHOUSE 2B |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
NEW YORK, NY 10023 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 5/18/2017 | M | 1680 | A | $2.38 | 3697 | D | |||
Common Stock | 5/18/2017 | M | 10084 | A | $1.67 | 13781 | D | |||
Common Stock | 5/18/2017 | M | 19281 | A | $2.38 | 33062 | D | |||
Common Stock | 5/18/2017 | P | 31045 | D (1) | $6.02 | 2017 | D | |||
Common Stock | 5/19/2017 | M | 11230 | A | $2.38 | 13247 | D | |||
Common Stock | 5/19/2017 | M | 11057 | A | $2.86 | 24304 | D | |||
Common Stock | 5/19/2017 | P | 22287 | D (2) | $6.07 | 2017 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Option to purchase Common Stock | $1.67 | 5/18/2017 | M | 10084 | (3) | 6/12/2017 | Common Stock | 10084.0 | $1.67 | 0 | D | ||||
Option to purchase Common Stock | $2.38 | 5/18/2017 | M | 1680 | (3) | 6/18/2018 | Common Stock | 1680.0 | $2.38 | 0 | D | ||||
Option to purchase Common Stock | $2.38 | 5/18/2017 | M | 19281 | (4) | 6/30/2019 | Common Stock | 19281.0 | $2.38 | 11230 | D | ||||
Option to purchase Common Stock | $2.38 | 5/19/2017 | M | 11230 | (4) | 6/30/2019 | Common Stock | 11230.0 | $2.38 | 0 | D | ||||
Option to purchase Common Stock | $2.86 | 5/19/2017 | M | 11057 | (5) | 12/17/2020 | Common Stock | 11057.0 | $2.86 | 0 | D |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Siber George
2000 BROADWAY PENTHOUSE 2B NEW YORK, NY 10023 |
X |
|
|
|
Signatures
|
||
/s/ Jonathan Poole, Attorney-in-Fact | 5/22/2017 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Genocea Biosciences Chart |
1 Month Genocea Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions